secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGENUS INC (AGEN)
CIK:        0001098972
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0000950170-25-068564
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agenus Q1 net loss $26.4M ($1.03/sh); cash burn reduced; BOT/BAL 100% pCR in dMMR CRC
--------------------------------------------------------------------------------

- Q1 2025 cash $18.5M (down from $40.4M Dec 2024); operating cash burn $25.6M vs $38.2M YoY.
- Net loss $26.4M ($1.03/sh) narrowed from $63.5M ($3.04/sh) Q1 2024; revenue $24.1M (non-cash royalty).
- On track to cut annualized cash burn below $50M in H2 2025; final stages of collaboration for cash infusion.
- BOT/BAL showed 100% pCR in dMMR CRC at higher dose; NEOASIS study responses in TNBC, sarcomas; HCC durable.
- Appointed Dr. Richard Goldberg as Chief Development Officer to lead BOT/BAL regulatory engagement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1098972/000095017025068564/0000950170-25-068564-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1098972/000095017025068564/agen-20250512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-068564

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer